10209. ASTRAIA I trimester (11 w.p.+0 d. - 13 w.p.+6 d.)

Comprehensive prenatal screening (ASTRAIA) is a modern method for the early detection of fetal chromosomal abnormality risks (trisomies 21, 18, and 13) based on the assessment of biochemical markers, ultrasound parameters, and individual maternal data. The analysis is performed using internationally recognized ASTRAIA software in accordance with FMF (Fetal Medicine Foundation) standards. This approach allows for highly accurate calculation of the individual risk of congenital developmental disorders and prompt clinical decisions regarding further management, such as monitoring, additional testing, or referral for NIPT. It is recommended for all pregnant women in the first trimester.

The ASTRAIA First Trimester Package (11 weeks + 0 days – 13 weeks + 6 days) is a combined prenatal study that covers a comprehensive assessment of the risk of fetal chromosomal abnormalities (trisomy 21 – Down syndrome, trisomy 18 – Edwards syndrome, trisomy 13 – Patau syndrome) in the first trimester of pregnancy. The calculation is performed using the international ASTRAIA program – software that complies with the standards of the Fetal Medicine Foundation (FMF, UK).

The package includes the determination of biochemical markers (free β-subunit of hCG and PAPP-A) taking into account the patient’s personal parameters (age, weight, type of pregnancy, ethnic origin, medical history) and ultrasound results (nuchal translucency thickness, fetal body length, presence of nasal bone). The package is recommended for pregnant women at 11 weeks + 0 days – 13 weeks + 6 days.

This is aimed at the personalized risk assessment not only for chromosomal abnormalities but also for pregnancy complications such as preeclampsia, preterm labor, and intrauterine growth restriction syndrome. It helps make informed decisions about additional diagnostics (NIPT, invasive tests) and follow-up care.

Please note: To obtain a quote, you must provide a completed referral and an ultrasound scan (or, if possible, a copy) performed by a certified specialist with a valid FMF license. Please check for this license before visiting Synevo Laboratory. For more information, please contact the call center.

When:

From 11 weeks + 0 days to 13 weeks + 6 days of pregnancy (according to ultrasound data).

It is during this period that biochemical and ultrasound parameters are most informative for calculating individual risk.

Recommended for:

All pregnant women in the first trimester, according to the Order of the Ministry of Health of Ukraine dated August 9, 2022, No. 1437, 'On Approval of the Standards of Medical Care ""Normal Pregnancy"".'

Women wishing to receive a risk assessment for chromosomal abnormalities, preeclampsia, preterm birth, and fetal growth restriction syndrome (FGR).

Patients with increased reproductive risk:

• Age 35+
• Complications in previous pregnancies (miscarriages, preterm birth, fetal growth restriction, etc.)
• Multiple pregnancies
• History of chromosomal abnormalities in previous pregnancies or in the family.

Please note: To have the calculation performed, you must provide a doctor’s referral that must include the FMF certificate (license) number of the specialist who performed the ultrasound, as well as the results of the ultrasound performed by a certified FMF specialist. Before contacting the Laboratory Synevo, we recommend verifying that the doctor who performed the ultrasound examination has a valid FMF certificate (license).

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: